Legend Biotech reported an EPS of -$0.05, missing the forecast slightly. Revenue was $272.33 million, below the expected $274.72 million. The stock rose 2.93% in pre-market trading, indicating ...
Legend Biotech Corp. reported a robust performance for Q4 2024, driven by a significant increase in CARVICTI sales. The company achieved net sales of $334 million for CARVICTI, marking a 110% ...
Operator: Ladies and gentlemen, thank you for standing by. Welcome to Legend Biotech Reports Third Quarter 2024 Financial Results. At this time, all participants are in a listen-only mode. After the ...
Legend Biotech Corp (LEGN) reported its second-quarter earnings for 2025, revealing a significant increase in revenue but a larger-than-expected loss per share. The company’s revenue reached 255.06 ...
Legend Biotech Corp (LEGN) reported its third-quarter earnings for 2025, revealing a mixed performance that fell short of market expectations. The company posted an earnings per share (EPS) of -$0.05, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results